v3.26.1
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS - USD ($)
3 Months Ended
Mar. 31, 2026
Mar. 31, 2025
Operating expenses:    
Research and development $ (2,763,340) $ (2,257,010)
General and administrative (2,590,205) (2,112,366)
Total operating expenses (5,353,545) (4,369,376)
Loss from operations (5,353,545) (4,369,376)
Other income (expense):    
Interest income, net 93,052 40,413
Foreign exchange loss, net (165,173) (100,586)
Loss before income tax (5,425,666) (4,429,549)
Income tax (183,066) (100,509)
Net loss $ (5,608,732) $ (4,530,058)
Net loss per shares:    
Net loss per share attributable to common stockholders - basic $ (0.13) $ (0.16)
Net loss per share attributable to common stockholders - diluted $ (0.13) $ (0.16)
Weighted average common stock - basic 42,230,248 28,685,417
Weighted average common stock - diluted 42,230,248 28,685,417